Researchers report a case of S-ICD implantation in patient with ccTGA and DDD pacemaker
Reviewed by Emily Henderson, B.Sc.Nov 20 2020
In a new publication from Cardiovascular Innovations and Applications; Yu Zhang, Wen-Long Dai, Can-Can Lin, Qiao-Yuan Li and Cheng-Jun Guo from Beijing Anzhen Hospital, Capital Medical University, Beijing, China consider implantation of an S-ICD in a patient with a DDD pacemaker and congenitally corrected transposition of the great arteries.
Subcutaneous implantable cardioverter-defibrillator (S-ICD) therapy has become a viable alternative to conventional transvenous ICD implantation.
- Machine learning algorithms help predict out-of-hospital cardiac arrest survival
- Study examines link between SARS-CoV-2 genomic load and COVID-19 patient outcomes
- Black, Latinx hospital workers at highest risk for SARS-CoV-2 infection, study finds
Patients with congenitally corrected transposition of the great arteries (ccTGA) have a high risk of sudden cardiac death due to malignant arrhythmia. The interaction between the S-ICD system and the transvenous pacemaker system is not fully understood.
The authors report a case of S-ICD implantation in a patient with ccTGA and a DDD pacemaker. The patient was a 30-year-old man with a previously placed pacemaker with diagnoses of congenital heart disease, ccTGA (SLL), left atrioventricular valve insufficiency, and third-degree atrioventricular block.
He presented with an out-of-hospital cardiac arrest, and an S-ICD was implanted to prevent sudden cardiac death. Defibrillation checks were performed successfully.
The authors tested the compatibility of the DDD pacemaker with the S-ICD and found that there was no interference between them. In conclusion, an S-ICD system is a reasonable and safe option in patients with ccTGA.